✦ LIBER ✦

P.40 Oral vinorelbine and gemcitabine (oVG) versus docetaxel and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis for elderly patients of a phase III randomized trial from the Hellenic Oncology Research Group (HORG)

✍ Scribed by Vamvakas, L.; Karampeazis, A.; Agelaki, S.; Agelidou, A.; Kotsakis, A.; Kakolyris, S.; Polyzos, A.; Pallis, A.; Saloustros, E.; Georgoulias, V.

Book ID: 123137150
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 57 KB
Volume: 64
Category: Article
ISSN: 1040-8428
DOI: 10.1016/S1040-8428(13)70213-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O12 FOLFOXIRI versus FOLFIRI as first li

O12 FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Androulakis, N.; Syrigos, K.; Polyzos, A.; Ziras, N.; Athanasiadis 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 62 KB

P.39 Docetaxel plus epirubicin (DE) vs d

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

6501 ORAL Global Lung Oncology Branch tr

6501 ORAL Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Rolski, J.; Grodzki, T.; Schneider, C.P.; Zatloukal, P.; Reck, M.; Aitini, E.; T 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Paclitaxel plus cisplatin is as effectiv

Paclitaxel plus cisplatin is as effective as regimens containing gemcitabine in people with advanced non-small cell lung cancer: Abstracted from: Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909–17.

✍ Sarah Danson 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 163 KB